Option Care signs on to provide Radicava

 - 
Wednesday, November 1, 2017

BANNOCKBURN, Ill. – Option Care Enterprises has become a nationally contracted home infusion provider of Radicava, the first ALS treatment option approved by the U.S. Food and Drug Administration, and has partnered with the ALS Association. Already, Option Care has started more than 100 patients with ALS on Radivaca. “Option Care applauds The ALS Association’s mission and recognizes their efforts in giving help and hope to those facing the disease,” said John Rademacher, CEO, Option Care. “We look forward to this new partnership with The ALS Association and the ability to be part of providing education, support and services to those living with the disease.” In addition, Option Care provides a nutrition support program and enteral therapy to ALS patients. The provider has a multidisciplinary team of more than 1,800 clinicians, including pharmacists, nurses and dieticians, to provide home infusion services for patients nearly across the country.